Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Gastrointestinal 2Breast 2Sarcoma 1Gynecologic 1Genitourinary 1

Conditions

Colorectal Neoplasms 3Pancreatic Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Kidney Neoplasms 1Gallbladder Neoplasms 1Fibromatosis, Gingival, 2 1Esophageal Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

pembrolizumab 29Cetuximab 11Nivolumab 10Fluorouracil 8Cyclophosphamide 8Cisplatin 8Carboplatin 8fludarabine 7atezolizumab 7Blood Specimen Collection 7cemiplimab 6Radiotherapy 6Drug Therapy 6Immune Checkpoint Inhibitors 5Gemcitabine 5Paclitaxel 4Docetaxel 4Capecitabine 4Biopsy 4spartalizumab 3avelumab 3Surveys and Questionnaires 3Pemetrexed 3Oncolytic Virotherapy 3Nicotine 3Magnetic Resonance Spectroscopy 3Irinotecan 3Ipilimumab 3Interleukin-2 3Bortezomib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × seribantumab × Gastrointestinal × Clear all
NCT04383210 2025-04-03

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Elevation Oncology

Phase 2 Terminated
54 enrolled 11 charts
BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Fibromatosis, Gingival, 2, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Uterine Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT01451632 2016-09-08

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Merrimack Pharmaceuticals

Phase 1 Completed
48 enrolled 14 charts
BreastGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡